CELESTIAL-TNCLL: An ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naïve (TN) CLL.Mazyar Shadman, Piers Patten, Talha Munir et al.|Journal of Clinical Oncology|2024Cited by 8
CaDAnCe-304, a phase 3, open-label, randomized study to evaluate the safety and efficacy of Bruton tyrosine kinase degrader BGB-16673 compared with pirtobrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphomaMeghan C. Thompson, John F. Seymour, Constantine S. Tam et al.|Blood|2025Cited by 1